The Space Sector Is Surging. Should You Buy AST SpaceMobile and Rocket Lab?

SpaceX is expected to file an IPO prospectus imminently, reportedly planning to raise $75B and implying a $1.75T valuation. The news sparked big swings in space equities: AST SpaceMobile jumped 10.4% Wednesday then gave back 8.5% Thursday, Rocket Lab rose 10.3% then fell 9.5%. Valuation concerns drive the caution—AST trades at ~325x sales and has no earnings, Rocket Lab trades near ~60x trailing sales—author recommends against buying these names now; disclosure notes Motley Fool and the author hold positions in these stocks.

Analysis

The market reaction shows a classic headline-driven rotation: short-duration liquidity chases ‘platform’ narratives then quickly reverts as discretionary traders lock gains and quant funds fade momentum. That creates multi-day volatility in small-cap space names and amplifies any divergence between cash-generative launchers and pre-revenue playbooks. Expect intraday spikes followed by 24–72 hour mean reversion windows as options gamma and retail flows unwind.

Second-order winners are intermediaries that monetize issuance activity (exchanges, banks, equity derivatives desks) and parts suppliers with diversified, contracted revenue; losers are pure-play pre-revenue retailers and suppliers dependent on dilutive capital raises. A large valuation anchor installed by a marquee listing compresses the relative multiple for adjacent smallcaps and raises the bar for fundraising and M&A — companies without visible EBITDA will face longer funding windows and higher dilution. Watch credits for satellite component vendors and small-launcher suppliers: tighter equity comps can slow receivables financing and extend order-to-cash cycles by quarters.

Near-term catalysts that will re-rate names are: formal prospectus disclosures (unit economics, free cash flow paths), follow-on secondary clocks/lockups, and changes in analyst coverage or index inclusion probabilities. Tail risks include a broader risk-off that kills IPO appetite (weeks), a surprise disclosure that materially de-rates the benchmark issuer (days), or conversely a strategic partnership flow-through that benefits selected suppliers (months). Strategy should be asymmetric: harvest theta where momentum is likely to fall out, but keep optionality to add to high-quality launchers on real earnings inflection points within 6–12 months.

Key Decisions for Investors

• Short ASTS via a defined-risk put spread (90-day): buy ATM put, sell 25–30% OTM put sized 0.75% NAV. Rationale: capture fast mean-reversion and higher implied vols; target 2.0–4.0x premium if shares fall 25–35%. Max loss = premium paid; stop-loss if ASTS rallies +15% from entry.
• Pair trade — Long RKLB / Short ASTS (3–6 month horizon): allocate 1.0% NAV long RKLB equity or call spread and 0.75% NAV short ASTS exposure (equity or puts) to isolate operational vs narrative risk. Rationale: long RKLB captures cash-generation path while short ASTS shorts narrative multiple compression; target 20–40% net return if sector sentiment normalizes, stop if sector-wide rotation exceeds +20%.
• Buy RKLB call spread (6–12 months) to express operational optionality: buy a 30% ITM call and sell a 100% OTM call, size 1.0% NAV. Rationale: asymmetric upside if company hits profitability milestones with capped premium; expected win if shares re-rate 30–60% upon confirmed EBITDA beats. Max loss = premium; take profits at 50–70% of max payoff.
• Long NDAQ exposure (6–12 months): buy NDAQ outright or a 12-month 10% OTM call (size 0.5–1.0% NAV) to play fee capture from elevated issuance and increased options flow. Rationale: exchange operators monetize a sustained IPO wave with high-margin revenues; target 20–35% upside, risk limited to premium if issuance environment cools.